ACLARION INC

NASDAQ: ACONW (Aclarion Inc)

最近更新时间: 16小时之前

0.029

0.01 (35.51%)

前收盘价格 0.021
成交量 70,421
52周波幅
0.024 (-18%) — 0.029 (0%)
营业利益率 (TTM) -10,789.22%
稀释每股收益 (EPS TTM) -6.58
季度收入增长率 (YOY) 78.10%
总债务/股东权益 (D/E MRQ) 47.32%
流动比率 (MRQ) 14.17
营业现金流 (OCF TTM) -8.95 M
杠杆自由现金流 (LFCF TTM) -5.60 M
资产报酬率 (ROA TTM) -45.78%
股东权益报酬率 (ROE TTM) -74.07%

AIStockmoo 评分

-0.4
负债低。盈利能力弱。短期流动性充足。现金流为负。 参考
来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 NA
相对估值 参考 NA
隐含增长 参考 NA
历史估值 参考 NA
资本回报 参考 NA
盈利趋势 参考 NA
持仓估值 参考 NA
风险溢价 参考 NA
市场估值 参考 NA
来自我们对走势图的 AI 技术分析。 参考 NA
趋势强度 参考 NA
技术形态 参考 NA
K线形态 参考 NA
中期趋势 参考 NA
近期没有目标价,因此依据目标价的调整方向。 参考
持仓情绪 参考 NA
新闻情绪 参考 NA
空头持仓从31 Aug到30 Oct 2026变化+16.8%,回补天数7.1天(FINRA)。 参考
内部交易活动 参考 NA
机构资金流 参考 NA
市场环境偏谨慎。 参考
行业表现优于大市。
只有一个支柱有明确读数,评分不变。
价格波动 参考 NA
短、中、长期均无明确趋势。 参考
支撑与阻力没有明确信号。 参考
最终评分 -0.39
全部展开

市场趋势

短期 中期
行业 Health Information Services (US) 混合的 看跌
Health Information Services (全球的) 混合的 看跌
股票 Aclarion Inc - -

相关股票

股票 市值 DY P/E(TTM) P/B 评分
ACONW - - - - -0.4
CARL 477 M - - 6.29 1.6
SY 166 M - - 0.770 -2.9
OTRKP - - - - -2.9
TEM 10 B - - 19.68 -0.1
HQY 8 B - 34.21 4.05 0.0

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. The company develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in Broomfield, Colorado.

部门 Healthcare
行业 Health Information Services

所有权

姓名 日期 持有股份
Captrust Financial Advisors 30 Sep 2026 63,400

该时间范围内无数据。

机构

空头持仓

结算日 股数 回补天数
30 Oct 2026 81,593 7.1
15 Oct 2026 73,843 4.2
30 Sep 2026 67,490 5.6
15 Sep 2026 66,327 27.1
31 Aug 2026 69,875 8.3
14 Aug 2026 231,797 4.2

来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。

日期 类型 细节
28 Oct 2026 Yahoo Finance Bausch + Lomb (BLCO) Surpasses Q3 Earnings and Revenue Estimates
Bausch + Lomb (BLCO) delivered earnings and revenue surprises of +61.91% and +0.14%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
27 Oct 2026 Yahoo Finance HCA Healthcare (HCA) Q3 Earnings and Revenues Top Estimates
HCA (HCA) delivered earnings and revenue surprises of +7.12% and +2.50%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
22 Oct 2026 Yahoo Finance Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs
Study conducted at London Spine Clinic found Nociscan's noninvasive scan successfully identified painful discs, agreeing with discography, the invasive gold standard, in up to 87% of casesNociscan also spared patients the needles, added cost, and recovery time that is often associated with…
20 Oct 2026 Yahoo Finance Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026
85% year-over-year scan volume growth in Q3 2026, contributing to 117% growth for the nine months ended September 30, 2026European Spine Journal publishes peer-reviewed data supporting MRS as a potential viable alternative to provocative discographyCLARITY trial expanded to eleven clinical sites…
13 Oct 2026 Yahoo Finance Aclarion to Present at the 20th Annual LD Micro Main Event
BROOMFIELD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion (NASDAQ: ACON) announced today that it will participate in the 20th Annual LD Micro Main Event, taking place October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. Aclarion is scheduled to present on Tuesday…
08 Oct 2026 Yahoo Finance Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment
New criteria fully approved at nine of eleven active sites expected to significantly accelerate enrollment paceInitial readout timing to be updated by year-end based on demonstrated Q4 enrollment increasesOverall trial duration remains on track BROOMFIELD, Colo., Oct. 08, 2026 (GLOBE NEWSWIRE)…
29 Sep 2026 Yahoo Finance Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
NYU Langone Health is a nationally recognized academic medical center with deep expertise in spine surgery, minimally invasive procedures, robotic spine surgery, and clinical researchCLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical…

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

风险 / 回报
TP1:
TP2:

以入场价计算,止损的亏损相对每个目标价的盈利。通常追求 2 或以上的比率。

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票